IL295797A - Human transfer receptor binding peptide - Google Patents

Human transfer receptor binding peptide

Info

Publication number
IL295797A
IL295797A IL295797A IL29579722A IL295797A IL 295797 A IL295797 A IL 295797A IL 295797 A IL295797 A IL 295797A IL 29579722 A IL29579722 A IL 29579722A IL 295797 A IL295797 A IL 295797A
Authority
IL
Israel
Prior art keywords
amino acid
seq
peptide
residue
modified
Prior art date
Application number
IL295797A
Other languages
English (en)
Hebrew (he)
Original Assignee
Japan Chem Res
Peptidream Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Chem Res, Peptidream Inc filed Critical Japan Chem Res
Publication of IL295797A publication Critical patent/IL295797A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL295797A 2020-02-22 2021-02-22 Human transfer receptor binding peptide IL295797A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020028879 2020-02-22
PCT/JP2021/006709 WO2021167107A1 (ja) 2020-02-22 2021-02-22 ヒトトランスフェリンレセプター結合ペプチド

Publications (1)

Publication Number Publication Date
IL295797A true IL295797A (en) 2022-10-01

Family

ID=77390874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295797A IL295797A (en) 2020-02-22 2021-02-22 Human transfer receptor binding peptide

Country Status (9)

Country Link
US (1) US20230203098A1 (2)
EP (1) EP4108676A4 (2)
JP (2) JP7796636B2 (2)
CN (1) CN115151556A (2)
AU (1) AU2021224412A1 (2)
CA (1) CA3171988A1 (2)
IL (1) IL295797A (2)
TW (1) TW202140513A (2)
WO (1) WO2021167107A1 (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117957240A (zh) * 2021-08-19 2024-04-30 肽梦想株式会社 人转铁蛋白受体结合肽
US20240390508A1 (en) * 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
WO2023027125A1 (ja) 2021-08-24 2023-03-02 ペプチドリーム株式会社 ヒトトランスフェリンレセプター結合抗体－ペプチドコンジュゲート
EP4230638A1 (en) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
AU2023331268A1 (en) 2022-08-26 2025-03-06 Peptidream Inc. Cycloalkyne derivative
EP4626906A1 (en) * 2022-11-29 2025-10-08 Vacino Biotech Co., Ltd. Transporter peptides and application thereof
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
JPWO2024195710A1 (2) * 2023-03-17 2024-09-26

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60147718A (ja) 1984-01-12 1985-08-03 Seikosha Co Ltd 太陽電池付きカラ−表示素子
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
JPH06228199A (ja) 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2007066627A1 (ja) 2005-12-06 2007-06-14 The University Of Tokyo 多目的アシル化触媒とその用途
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
KR20140026372A (ko) 2011-02-02 2014-03-05 이무노퓨처 아이앤씨. 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도
CA3092114A1 (en) 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
BR112014022435B1 (pt) * 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
HUE045144T2 (hu) 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
US20160068835A1 (en) 2013-01-30 2016-03-10 Peptidream Inc. Flexible display method
CN103254280A (zh) * 2013-03-07 2013-08-21 广州暨南大学医药生物技术研究开发中心 具有肿瘤细胞靶向结合能力的短肽及其应用
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
CA3052936A1 (en) * 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
IL276327B2 (en) 2018-02-05 2024-05-01 Japan Chem Res Method for delivering drug to muscle

Also Published As

Publication number Publication date
JPWO2021167107A1 (2) 2021-08-26
US20230203098A1 (en) 2023-06-29
JP7796636B2 (ja) 2026-01-09
CN115151556A (zh) 2022-10-04
EP4108676A4 (en) 2024-06-05
EP4108676A1 (en) 2022-12-28
TW202140513A (zh) 2021-11-01
CA3171988A1 (en) 2021-08-26
AU2021224412A1 (en) 2022-09-15
JP2026032056A (ja) 2026-02-25
WO2021167107A1 (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
IL295797A (en) Human transfer receptor binding peptide
AU2009280021B2 (en) Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
JP2026032056A5 (2)
US9072703B2 (en) Glucose-dependent insulinotropic polypeptide analogues
JP2022513223A5 (2)
JP2013518115A5 (2)
JPH0532696A (ja) 副甲状腺ホルモン誘導体
RU2008141280A (ru) Агонисты рецептора нейромедина u и их применение
RU2011134596A (ru) Аналоги оксинтомодулина
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
CA2069943A1 (en) Synthetic calcitonin peptides
EP3897708A1 (en) Lipopeptide building blocks and synthetic virus-like particles
US7402663B2 (en) Modified peptide
US10632187B2 (en) Hemagglutinin-binding peptide
AU2022222674A9 (en) Glucagon-like peptide-1 receptor antagonists
AU2002238701A1 (en) Modified derivatives of CCK-8
CA2294996C (en) Angiotensin derivatives
Sakura et al. Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity
WO2021260176A1 (en) Synthetic epitopes of betacoronaviruses
JP2005126360A (ja) 新規なポリペプチドで構成されたコラゲナーゼ阻害剤
SI9300595B (sl) Peptidi z organo-protektivno aktivnostjo, postopki za njihovo pripravo in njihova uporaba v terapiji
KR20240045202A (ko) Ghr-결합 펜딩 펩티드 및 이를 포함하는 조성물
HK40083520A (en) Human transferrin receptor binding peptide
JPH05339288A (ja) Ｈｉｖ感染阻止活性を有するペプチド